NovaBay Pharmaceuticals, Inc.
NBY
$1.02
$0.088.50%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -78.51% | -- | -- | 8.60% | -1.90% |
| Total Other Revenue | -- | -- | -- | 89.29% | 70.00% |
| Total Revenue | -78.66% | -- | -- | 9.90% | -1.61% |
| Cost of Revenue | -- | -- | -- | -20.73% | -- |
| Gross Profit | -- | -- | -- | 38.69% | -- |
| SG&A Expenses | -28.89% | 16.94% | 17.90% | 32.87% | -27.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.76% | 16.94% | 17.90% | 15.73% | -46.43% |
| Operating Income | 31.36% | -16.94% | -17.90% | -27.88% | -143.98% |
| Income Before Tax | 28.10% | 8.61% | -13.85% | 23.04% | -37.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.10% | 8.61% | -13.85% | 23.04% | -37.03% |
| Earnings from Discontinued Operations | -93.77% | -92.55% | 3,906.23% | 104.65% | 258.91% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.68% | -21.26% | 338.64% | 70.50% | 31.02% |
| EBIT | 31.36% | -16.94% | -17.90% | -27.88% | -143.98% |
| EBITDA | 31.23% | -17.32% | -18.43% | -28.61% | -147.74% |
| EPS Basic | 88.54% | 75.92% | 104.82% | 99.67% | 85.36% |
| Normalized Basic EPS | 86.70% | 81.13% | 97.93% | 98.10% | 84.21% |
| EPS Diluted | 88.40% | 75.75% | 104.82% | 99.67% | 85.32% |
| Normalized Diluted EPS | 86.70% | 81.13% | 97.97% | 98.10% | 84.21% |
| Average Basic Shares Outstanding | 408.74% | 403.72% | 4,323.33% | 3,956.32% | 761.94% |
| Average Diluted Shares Outstanding | 408.74% | 403.72% | 4,412.50% | 3,956.32% | 761.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |